Article: Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration
Colloids and Surfaces B: Biointerfaces. 2015 Oct. 01, v. 134
2015
Abstract: The remarkable increase in the prevalence of neurodegenerative diseases has become a serious public health problem. Considering the lack of effective treatments to address these diseases and the difficulties in accessing the brain due to the bloodâ ... ...
| Abstract | The remarkable increase in the prevalence of neurodegenerative diseases has become a serious public health problem. Considering the lack of effective treatments to address these diseases and the difficulties in accessing the brain due to the bloodâbrain barrier (BBB), to attain a successful strategy to improve drug delivery to the brain, the administration route becomes a point of interest. The intranasal route provides a non-invasive method to bypass the BBB. Moreover, the development of new technologies for the protection and delivery of peptides is an interesting approach to consider. Thus, in this work, a suitable chitosan coated nanostructured lipid carrier (CS-NLC) formulation with the capacity to reach the brain after being intranasally administered was successfully developed and optimized. The optimal formulation displayed a particle size of 114nm with a positive surface charge of +28mV. The in vitro assays demonstrated the biocompatibility of the nanocarrier and its cellular uptake by 16HBE14o- cells. Furthermore, no haemagglutination or haemolysis processes were observed when the particles were incubated with erythrocytes, and no toxicity signals appeared in the nasal mucosa of mice after the administration of CS-NLCs. Finally, the biodistribution study of CS-NLC-DiR demonstrated an efficient brain delivery of the particles after intranasal administration. In conclusion, CS-NLC can be considered to be a safe and effective nanocarrier for nose-to-brain drug delivery; however, to obtain a higher concentration of the drug in the brain following intranasal administration, further modifications are warranted in the CS-NLC formulation. |
|---|---|
| Keywords | biocompatibility ; blood-brain barrier ; brain ; chitosan ; colloids ; drugs ; erythrocytes ; hemagglutination ; hemolysis ; in vitro studies ; intranasal administration ; lipids ; mice ; nanocarriers ; nasal mucosa ; neurodegenerative diseases ; particle size ; peptides ; proteins ; public health ; toxicity |
| Language | English |
| Dates of publication | 2015-1001 |
| Size | p. 304-313. |
| Publishing place | Elsevier B.V. |
| Document type | Article |
| ZDB-ID | 1500523-9 |
| ISSN | 1873-4367 ; 0927-7765 |
| ISSN (online) | 1873-4367 |
| ISSN | 0927-7765 |
| DOI | 10.1016/j.colsurfb.2015.06.054 |
| Database | NAL-Catalogue (AGRICOLA) |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.